Contact
Please use this form to send email to PR contact of this press release:
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCARâ„¢ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
TO: